Methamphetamine Abuse, Substance Use Disorders
Conditions
Brief summary
This investigation will be the first study assessing genetic modulation of naltrexone's NTX effects upon the abuse liability of a stimulant drug (methamphetamine). The study team will assess the ability of oral NTX to block the reinforcing and positive subjective effects of intranasal (IN) methamphetamine (30mg/70kg). This investigation could identify an important Gene x Pharmacological interaction, contributing to the personalization of stimulant abuse pharmacotherapy.
Detailed description
A recent meta-analysis concluded that the OPRM1 A118G SNP (rs1799971) significantly moderates the treatment efficacy of Naltrexone (NTX) in treating alcohol abuse, increasing the treatment efficacy by over 2-fold among G-allele carriers (AG/GG). The proposed application would be the first to investigate the moderating effect of this genotype in the efficacy of NTX to treat stimulant abuse. More specifically, the study team proposes to investigate the interaction between NTX and intranasal (IN) methamphetamine (30mg/70kg). Participants who meet DSM criteria for mild-to-severe stimulant use disorder (N=up to 70) will complete 4 testing sessions where drug effects are tested following pretreatment with NTX (0, 50 mg). Naltrexone pretreatment effects upon the abuse liability of IN methamphetamine will be assessed using self-report measurements of positive subjective effects and drug self-administration. Medication effects on these validated predictors of abuse potential will be compared between A118G A allele homozygotes (AA) and G-allele carriers (AG/GG; an anticipated 25% of the total sample), in order to assess genetic moderation of treatment outcome.
Interventions
DRUGIntranasal Methamphetamine
Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
Sponsors
New York State Psychiatric Institute
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Masking description
Participants and study staff conducting the lab sessions will be blinded to the treatment condition (i.e., naltrexone 0 mg or 50 mg)
Intervention model description
Participants will complete two testing sessions in which the effects of oral naltrexone (0 mg & 50 mg) will be tested in combination with intranasal methamphetamine. Participants will complete two testing sessions (naltrexone 0 mg + Methamphetamine & naltrexone 50 mg + methamphetamine), in randomized order.
Eligibility
Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female age 21 to 50 years 2. DSM-5 criteria for mild-to-severe stimulant use disorder, along with intravenous, intranasal or smoked use of amphetamine-type stimulants in amounts equal to or greater than administered in the current study. 3. Able to give written informed consent to participate. 4. Females must be either post-menopausal, surgically sterilized, or using an acceptable method of contraception (double-barrier method like a condom with a spermicidal lubricant) to participate in this study. 5. Racially Caucasian or of European descent.
Exclusion criteria
1. Currently seeking treatment for a substance use disorder. 2. DSM-5 criteria for moderate-to-severe substance use disorders (except those involving cocaine, amphetamines and nicotine). 3. Psychiatric condition that may affect the participants' ability to provide informed consent (e.g., psychotic disorder), or make participation hazardous for the participant or study staff (e.g., severe depression/suicidality, or risk of violence). 4. Uncontrolled neurological, cardiovascular, and hepatic diseases, active tuberculosis, or any other disorder that might make administration of study medications hazardous. 5. Gastrointestinal or renal disease that would significantly impair absorption, metabolism or excretion of study drug, or require medication or medical treatment. 6. Current treatment with a psychotropic medication that in the physician's judgement would interfere with the study endpoints. 7. History of allergy, adverse reaction, or sensitivity to amphetamines. 8. Medical conditions that may make study participation hazardous: * History of seizures or cardiac risk conditions (unstable angina, cardiac arrhythmias, chest pain, strong palpitations (subjectively defined as the feeling that the heart is beating too hard, too fast, skipping a beat, or fluttering). * Elevated liver function tests (i.e., AST and ALT \> 3 times the upper limit of normal). * Impaired renal function (creatinine \> 1.2). * Hypertension (\>140/90). * Asthmatic symptoms within the past 3 years.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Methamphetamine Self-Administration | 1 day. | To assess the reinforcing effects of methamphetamine, participants complete a drug self-administration procedure. The outcome measure for this procedure is the number of operant responses (clicks on a mouse) participant are willing to make in order to receive drug (methamphetamine). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Positive Subjective Effects of Methamphetamine. | 1 day | Participant ratings of methamphetamine Liking, on a 100 mm visual analog scale. Participants are asked to indicate on a 100 mm line the extent to which they agree with the description of the drug provided. The 0 mm end of the line indicates Not at All, while the 100 mm indicates Extremely. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Naltrexone 0mg First, Then Naltrexone 50mg This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight) | 8 |
| Naltrexone 50mg First, Then Naltrexone 0mg This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight) | 6 |
| Total | 14 |
Baseline characteristics
| Characteristic | Naltrexone 0mg First, Then Naltrexone 50mg | Total | Naltrexone 50mg First, Then Naltrexone 0mg |
|---|---|---|---|
| Age, Continuous | 35.1 years STANDARD_DEVIATION 6.5 | 33.4 years STANDARD_DEVIATION 7.9 | 31.7 years STANDARD_DEVIATION 9.3 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 6 Participants | 10 Participants | 4 Participants |
| Region of Enrollment United States | 8 participants | 14 participants | 6 participants |
| Sex: Female, Male Female | 0 Participants | 1 Participants | 1 Participants |
| Sex: Female, Male Male | 8 Participants | 13 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 14 | 0 / 14 |
| other Total, other adverse events | 0 / 14 | 0 / 14 |
| serious Total, serious adverse events | 0 / 14 | 0 / 14 |
Outcome results
Primary
Methamphetamine Self-Administration
To assess the reinforcing effects of methamphetamine, participants complete a drug self-administration procedure. The outcome measure for this procedure is the number of operant responses (clicks on a mouse) participant are willing to make in order to receive drug (methamphetamine).
Time frame: 1 day.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Naltrexone 0 mg | Methamphetamine Self-Administration | 8890 Clicks on a computer mouse | Standard Deviation 3509 |
| Naltrexone 50 mg | Methamphetamine Self-Administration | 7116 Clicks on a computer mouse | Standard Deviation 3080 |
Secondary
Positive Subjective Effects of Methamphetamine.
Participant ratings of methamphetamine Liking, on a 100 mm visual analog scale. Participants are asked to indicate on a 100 mm line the extent to which they agree with the description of the drug provided. The 0 mm end of the line indicates Not at All, while the 100 mm indicates Extremely.
Time frame: 1 day
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Naltrexone 0 mg | Positive Subjective Effects of Methamphetamine. | 53.6 units on a scale | Standard Deviation 38.9 |
| Naltrexone 50 mg | Positive Subjective Effects of Methamphetamine. | 57.2 units on a scale | Standard Deviation 32.5 |